#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Extracellular vesicles ( EVs ) are cell-derived membrane vesicles that represent an endogenous mechanism for intercellular communication .
2-1	16-29	Extracellular	abstract[2]	new[2]	appos	2-4[0_2]
2-2	30-38	vesicles	abstract[2]	new[2]	_	_
2-3	39-40	(	_	_	_	_
2-4	41-44	EVs	abstract	giv	coref	2-7[5_0]
2-5	45-46	)	_	_	_	_
2-6	47-50	are	_	_	_	_
2-7	51-63	cell-derived	abstract[5]	giv[5]	coref	3-1[0_5]
2-8	64-72	membrane	object|abstract[5]	new|giv[5]	coref	3-52[23_0]
2-9	73-81	vesicles	abstract[5]	giv[5]	_	_
2-10	82-86	that	abstract[5]	giv[5]	_	_
2-11	87-96	represent	abstract[5]	giv[5]	_	_
2-12	97-99	an	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-13	100-110	endogenous	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-14	111-120	mechanism	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-15	121-124	for	abstract[5]|abstract[6]	giv[5]|new[6]	_	_
2-16	125-138	intercellular	abstract[5]|abstract[6]|abstract[7]	giv[5]|new[6]|new[7]	_	_
2-17	139-152	communication	abstract[5]|abstract[6]|abstract[7]	giv[5]|new[6]|new[7]	_	_
2-18	153-154	.	_	_	_	_

#Text=EVs can be classified in exosomes , nano-sized vesicles ( with a diameter in the range of 30 to 120 nm ) , that originate from the cell endocytic compartment through the formation of multivesicular bodies ( MVB ) , microvesicles , with a diameter up to 1 μm released by cell membrane budding , and apoptotic bodies , with a dimension similar to platelets , derived from blebbing of dying cells .
3-1	155-158	EVs	abstract	giv	coref	3-8[10_0]
3-2	159-162	can	_	_	_	_
3-3	163-165	be	_	_	_	_
3-4	166-176	classified	_	_	_	_
3-5	177-179	in	_	_	_	_
3-6	180-188	exosomes	abstract	new	coref	5-14[43_0]
3-7	189-190	,	_	_	_	_
3-8	191-201	nano-sized	abstract[10]	giv[10]	coref	6-1[0_10]
3-9	202-210	vesicles	abstract[10]	giv[10]	_	_
3-10	211-212	(	abstract[10]	giv[10]	_	_
3-11	213-217	with	abstract[10]	giv[10]	_	_
3-12	218-219	a	abstract[10]|abstract[11]	giv[10]|new[11]	coref	3-44[20_11]
3-13	220-228	diameter	abstract[10]|abstract[11]	giv[10]|new[11]	_	_
3-14	229-231	in	abstract[10]|abstract[11]	giv[10]|new[11]	_	_
3-15	232-235	the	abstract[10]|abstract[11]|abstract[12]	giv[10]|new[11]|new[12]	_	_
3-16	236-241	range	abstract[10]|abstract[11]|abstract[12]	giv[10]|new[11]|new[12]	_	_
3-17	242-244	of	abstract[10]|abstract[11]|abstract[12]	giv[10]|new[11]|new[12]	_	_
3-18	245-247	30	abstract[10]|abstract[11]|abstract[12]|abstract[13]	giv[10]|new[11]|new[12]|new[13]	_	_
3-19	248-250	to	abstract[10]|abstract[11]|abstract[12]|abstract[13]	giv[10]|new[11]|new[12]|new[13]	_	_
3-20	251-254	120	abstract[10]|abstract[11]|abstract[12]|abstract[13]	giv[10]|new[11]|new[12]|new[13]	_	_
3-21	255-257	nm	abstract[10]|abstract[11]|abstract[12]|abstract[13]	giv[10]|new[11]|new[12]|new[13]	_	_
3-22	258-259	)	abstract[10]	giv[10]	_	_
3-23	260-261	,	_	_	_	_
3-24	262-266	that	_	_	_	_
3-25	267-276	originate	_	_	_	_
3-26	277-281	from	_	_	_	_
3-27	282-285	the	place[15]	new[15]	_	_
3-28	286-290	cell	place|place[15]	new|new[15]	coref	3-52
3-29	291-300	endocytic	place[15]	new[15]	_	_
3-30	301-312	compartment	place[15]	new[15]	_	_
3-31	313-320	through	_	_	_	_
3-32	321-324	the	event[16]	new[16]	ana	4-24[0_16]
3-33	325-334	formation	event[16]	new[16]	_	_
3-34	335-337	of	event[16]	new[16]	_	_
3-35	338-352	multivesicular	event[16]|object[17]	new[16]|new[17]	coref	3-57[25_17]
3-36	353-359	bodies	event[16]|object[17]	new[16]|new[17]	_	_
3-37	360-361	(	_	_	_	_
3-38	362-365	MVB	abstract	new	_	_
3-39	366-367	)	_	_	_	_
3-40	368-369	,	_	_	_	_
3-41	370-383	microvesicles	animal[19]	new[19]	coref	5-17[0_19]
3-42	384-385	,	animal[19]	new[19]	_	_
3-43	386-390	with	animal[19]	new[19]	_	_
3-44	391-392	a	animal[19]|abstract[20]	new[19]|giv[20]	_	_
3-45	393-401	diameter	animal[19]|abstract[20]	new[19]|giv[20]	_	_
3-46	402-404	up	animal[19]|abstract[20]|abstract[21]	new[19]|giv[20]|new[21]	_	_
3-47	405-407	to	animal[19]|abstract[20]|abstract[21]	new[19]|giv[20]|new[21]	_	_
3-48	408-409	1	animal[19]|abstract[20]|abstract[21]	new[19]|giv[20]|new[21]	_	_
3-49	410-412	μm	animal[19]|abstract[20]|abstract[21]	new[19]|giv[20]|new[21]	_	_
3-50	413-421	released	animal[19]|abstract[20]	new[19]|giv[20]	_	_
3-51	422-424	by	animal[19]|abstract[20]	new[19]|giv[20]	_	_
3-52	425-429	cell	animal[19]|abstract[20]|place|object[23]|object[24]	new[19]|giv[20]|giv|giv[23]|new[24]	coref|coref	10-14[88_23]|15-23
3-53	430-438	membrane	animal[19]|abstract[20]|object[23]|object[24]	new[19]|giv[20]|giv[23]|new[24]	_	_
3-54	439-446	budding	animal[19]|abstract[20]|object[24]	new[19]|giv[20]|new[24]	_	_
3-55	447-448	,	_	_	_	_
3-56	449-452	and	_	_	_	_
3-57	453-462	apoptotic	object[25]	giv[25]	_	_
3-58	463-469	bodies	object[25]	giv[25]	_	_
3-59	470-471	,	object[25]	giv[25]	_	_
3-60	472-476	with	object[25]	giv[25]	_	_
3-61	477-478	a	object[25]|abstract[26]	giv[25]|new[26]	_	_
3-62	479-488	dimension	object[25]|abstract[26]	giv[25]|new[26]	_	_
3-63	489-496	similar	object[25]|abstract[26]	giv[25]|new[26]	_	_
3-64	497-499	to	object[25]	giv[25]	_	_
3-65	500-509	platelets	object[25]|object	giv[25]|new	_	_
3-66	510-511	,	object[25]	giv[25]	_	_
3-67	512-519	derived	object[25]	giv[25]	_	_
3-68	520-524	from	object[25]	giv[25]	_	_
3-69	525-533	blebbing	object[25]|substance[28]	giv[25]|new[28]	_	_
3-70	534-536	of	object[25]|substance[28]	giv[25]|new[28]	_	_
3-71	537-542	dying	object[25]|substance[28]|animal[29]	giv[25]|new[28]|new[29]	coref	6-26[53_29]
3-72	543-548	cells	object[25]|substance[28]|animal[29]	giv[25]|new[28]|new[29]	_	_
3-73	549-550	.	_	_	_	_

#Text=Despite the distinct sizes and biogenesis , the absence of standardized isolation methods and the numerous similarities existing between these two subclasses make it particularly challenging to distinguish among them .
4-1	551-558	Despite	_	_	_	_
4-2	559-562	the	abstract[30]	new[30]	_	_
4-3	563-571	distinct	abstract[30]	new[30]	_	_
4-4	572-577	sizes	abstract[30]	new[30]	_	_
4-5	578-581	and	_	_	_	_
4-6	582-592	biogenesis	abstract	new	_	_
4-7	593-594	,	_	_	_	_
4-8	595-598	the	abstract[32]	new[32]	_	_
4-9	599-606	absence	abstract[32]	new[32]	_	_
4-10	607-609	of	abstract[32]	new[32]	_	_
4-11	610-622	standardized	abstract[32]|abstract[34]	new[32]|new[34]	_	_
4-12	623-632	isolation	abstract[32]|abstract|abstract[34]	new[32]|new|new[34]	_	_
4-13	633-640	methods	abstract[32]|abstract[34]	new[32]|new[34]	_	_
4-14	641-644	and	_	_	_	_
4-15	645-648	the	abstract[35]	new[35]	_	_
4-16	649-657	numerous	abstract[35]	new[35]	_	_
4-17	658-670	similarities	abstract[35]	new[35]	_	_
4-18	671-679	existing	abstract[35]	new[35]	_	_
4-19	680-687	between	_	_	_	_
4-20	688-693	these	abstract[36]	new[36]	ana	4-30[0_36]
4-21	694-697	two	abstract[36]	new[36]	_	_
4-22	698-708	subclasses	abstract[36]	new[36]	_	_
4-23	709-713	make	_	_	_	_
4-24	714-716	it	event	giv	_	_
4-25	717-729	particularly	_	_	_	_
4-26	730-741	challenging	_	_	_	_
4-27	742-744	to	_	_	_	_
4-28	745-756	distinguish	_	_	_	_
4-29	757-762	among	_	_	_	_
4-30	763-767	them	abstract	giv	_	_
4-31	768-769	.	_	_	_	_

#Text=In this review , we will use the generic term EVs to indicate both exosomes and microvesicles .
5-1	770-772	In	_	_	_	_
5-2	773-777	this	event[39]	new[39]	coref	23-7[191_39]
5-3	778-784	review	event[39]	new[39]	_	_
5-4	785-786	,	_	_	_	_
5-5	787-789	we	person	acc	ana	24-9
5-6	790-794	will	_	_	_	_
5-7	795-798	use	_	_	_	_
5-8	799-802	the	abstract[41]|abstract[42]	new[41]|new[42]	_	_
5-9	803-810	generic	abstract[41]|abstract[42]	new[41]|new[42]	_	_
5-10	811-815	term	abstract[41]|abstract[42]	new[41]|new[42]	_	_
5-11	816-819	EVs	abstract[42]	new[42]	_	_
5-12	820-822	to	_	_	_	_
5-13	823-831	indicate	_	_	_	_
5-14	832-836	both	abstract[43]|abstract[44]	giv[43]|giv[44]	coref	5-14[44_43]
5-15	837-845	exosomes	abstract[43]|abstract[44]	giv[43]|giv[44]	_	_
5-16	846-849	and	abstract[44]	giv[44]	_	_
5-17	850-863	microvesicles	abstract[44]|animal	giv[44]|giv	_	_
5-18	864-865	.	_	_	_	_

#Text=EVs have been shown to carry functionally active biological materials including proteins , mRNAs and miRNAs , which makes them capable of transmitting signals to target cells in the surrounding environment as well as to distant organs , via blood and lymphatic vessels .
6-1	866-869	EVs	abstract	giv	coref	7-13[62_0]
6-2	870-874	have	_	_	_	_
6-3	875-879	been	_	_	_	_
6-4	880-885	shown	_	_	_	_
6-5	886-888	to	_	_	_	_
6-6	889-894	carry	_	_	_	_
6-7	895-907	functionally	substance[47]	new[47]	_	_
6-8	908-914	active	substance[47]	new[47]	_	_
6-9	915-925	biological	substance[47]	new[47]	_	_
6-10	926-935	materials	substance[47]	new[47]	_	_
6-11	936-945	including	substance[47]	new[47]	_	_
6-12	946-954	proteins	substance[47]|substance	new[47]|new	coref	15-15[118_0]
6-13	955-956	,	substance[47]	new[47]	_	_
6-14	957-962	mRNAs	substance[47]|abstract	new[47]|new	_	_
6-15	963-966	and	substance[47]	new[47]	_	_
6-16	967-973	miRNAs	substance[47]|abstract[50]	new[47]|new[50]	ana	6-20[0_50]
6-17	974-975	,	substance[47]|abstract[50]	new[47]|new[50]	_	_
6-18	976-981	which	substance[47]|abstract[50]	new[47]|new[50]	_	_
6-19	982-987	makes	substance[47]|abstract[50]	new[47]|new[50]	_	_
6-20	988-992	them	substance[47]|abstract[50]|abstract	new[47]|new[50]|giv	_	_
6-21	993-1000	capable	substance[47]|abstract[50]	new[47]|new[50]	_	_
6-22	1001-1003	of	substance[47]|abstract[50]	new[47]|new[50]	_	_
6-23	1004-1016	transmitting	substance[47]|abstract[50]	new[47]|new[50]	_	_
6-24	1017-1024	signals	substance[47]|abstract[50]|abstract	new[47]|new[50]|new	_	_
6-25	1025-1027	to	_	_	_	_
6-26	1028-1034	target	animal[53]	giv[53]	coref	9-11[77_53]
6-27	1035-1040	cells	animal[53]	giv[53]	_	_
6-28	1041-1043	in	animal[53]	giv[53]	_	_
6-29	1044-1047	the	animal[53]|place[54]	giv[53]|new[54]	_	_
6-30	1048-1059	surrounding	animal[53]|place[54]	giv[53]|new[54]	_	_
6-31	1060-1071	environment	animal[53]|place[54]	giv[53]|new[54]	_	_
6-32	1072-1074	as	_	_	_	_
6-33	1075-1079	well	_	_	_	_
6-34	1080-1082	as	_	_	_	_
6-35	1083-1085	to	_	_	_	_
6-36	1086-1093	distant	object[55]	new[55]	coref	21-24[181_55]
6-37	1094-1100	organs	object[55]	new[55]	_	_
6-38	1101-1102	,	object[55]	new[55]	_	_
6-39	1103-1106	via	object[55]	new[55]	_	_
6-40	1107-1112	blood	object[55]|substance|object[57]	new[55]|new|new[57]	coref|coref	9-16|12-18[107_57]
6-41	1113-1116	and	object[55]|object[57]	new[55]|new[57]	_	_
6-42	1117-1126	lymphatic	object[55]|object[57]	new[55]|new[57]	_	_
6-43	1127-1134	vessels	object[55]|object[57]	new[55]|new[57]	_	_
6-44	1135-1136	.	_	_	_	_

#Text=The scientific community has recently turned its interest toward the evaluation of EVs as drug delivery vehicles .
7-1	1137-1140	The	organization[58]	new[58]	ana	7-7[0_58]
7-2	1141-1151	scientific	organization[58]	new[58]	_	_
7-3	1152-1161	community	organization[58]	new[58]	_	_
7-4	1162-1165	has	_	_	_	_
7-5	1166-1174	recently	_	_	_	_
7-6	1175-1181	turned	_	_	_	_
7-7	1182-1185	its	organization|abstract[60]	giv|new[60]	coref|coref	22-11[186_0]|22-10[187_60]
7-8	1186-1194	interest	abstract[60]	new[60]	_	_
7-9	1195-1201	toward	_	_	_	_
7-10	1202-1205	the	abstract[61]	new[61]	_	_
7-11	1206-1216	evaluation	abstract[61]	new[61]	_	_
7-12	1217-1219	of	abstract[61]	new[61]	_	_
7-13	1220-1223	EVs	abstract[61]|abstract[62]	new[61]|giv[62]	coref	8-5[0_62]
7-14	1224-1226	as	abstract[61]|abstract[62]	new[61]|giv[62]	_	_
7-15	1227-1231	drug	abstract[61]|abstract[62]|substance|abstract[64]|object[65]	new[61]|giv[62]|new|new[64]|new[65]	coref|coref|coref	8-11|8-12[0_64]|23-21[197_65]
7-16	1232-1240	delivery	abstract[61]|abstract[62]|abstract[64]|object[65]	new[61]|giv[62]|new[64]|new[65]	_	_
7-17	1241-1249	vehicles	abstract[61]|abstract[62]|object[65]	new[61]|giv[62]|new[65]	_	_
7-18	1250-1251	.	_	_	_	_

#Text=In this context , EVs offer significant advantages over current drug delivery systems , such as liposomes and polymeric nanoparticles .
8-1	1252-1254	In	_	_	_	_
8-2	1255-1259	this	abstract[66]	new[66]	_	_
8-3	1260-1267	context	abstract[66]	new[66]	_	_
8-4	1268-1269	,	_	_	_	_
8-5	1270-1273	EVs	abstract	giv	coref	9-2
8-6	1274-1279	offer	_	_	_	_
8-7	1280-1291	significant	abstract[68]	new[68]	_	_
8-8	1292-1302	advantages	abstract[68]	new[68]	_	_
8-9	1303-1307	over	abstract[68]	new[68]	_	_
8-10	1308-1315	current	abstract[68]|abstract[71]	new[68]|new[71]	coref	16-6[131_71]
8-11	1316-1320	drug	abstract[68]|substance|abstract[71]	new[68]|giv|new[71]	coref	10-26[90_0]
8-12	1321-1329	delivery	abstract[68]|abstract|abstract[71]	new[68]|giv|new[71]	coref	16-8
8-13	1330-1337	systems	abstract[68]|abstract[71]	new[68]|new[71]	_	_
8-14	1338-1339	,	abstract[68]|abstract[71]	new[68]|new[71]	_	_
8-15	1340-1344	such	abstract[68]|abstract[71]	new[68]|new[71]	_	_
8-16	1345-1347	as	abstract[68]|abstract[71]	new[68]|new[71]	_	_
8-17	1348-1357	liposomes	abstract[68]|abstract[71]|substance	new[68]|new[71]|new	coref	16-11
8-18	1358-1361	and	abstract[68]|abstract[71]	new[68]|new[71]	_	_
8-19	1362-1371	polymeric	abstract[68]|abstract[71]|object[73]	new[68]|new[71]|new[73]	coref	15-43[127_73]
8-20	1372-1385	nanoparticles	abstract[68]|abstract[71]|object[73]	new[68]|new[71]|new[73]	_	_
8-21	1386-1387	.	_	_	_	_

#Text=Since EVs can be obtained with an autologous procedure from the patient ’s cells or blood , they do not solicit the immune system as usual synthetic formulations do .
9-1	1388-1393	Since	_	_	_	_
9-2	1394-1397	EVs	abstract	giv	coref	10-9
9-3	1398-1401	can	_	_	_	_
9-4	1402-1404	be	_	_	_	_
9-5	1405-1413	obtained	_	_	_	_
9-6	1414-1418	with	_	_	_	_
9-7	1419-1421	an	event[75]	new[75]	_	_
9-8	1422-1432	autologous	event[75]	new[75]	_	_
9-9	1433-1442	procedure	event[75]	new[75]	_	_
9-10	1443-1447	from	_	_	_	_
9-11	1448-1451	the	animal[77]|animal[78]	giv[77]|giv[78]	coref|ana	9-11[78_77]|9-18[0_78]
9-12	1452-1459	patient	person[76]|animal[77]|animal[78]	new[76]|giv[77]|giv[78]	_	_
9-13	1460-1462	’s	person[76]|animal[77]|animal[78]	new[76]|giv[77]|giv[78]	_	_
9-14	1463-1468	cells	animal[77]|animal[78]	giv[77]|giv[78]	_	_
9-15	1469-1471	or	animal[78]	giv[78]	_	_
9-16	1472-1477	blood	animal[78]|substance	giv[78]|giv	_	_
9-17	1478-1479	,	_	_	_	_
9-18	1480-1484	they	animal	giv	_	_
9-19	1485-1487	do	_	_	_	_
9-20	1488-1491	not	_	_	_	_
9-21	1492-1499	solicit	_	_	_	_
9-22	1500-1503	the	abstract[81]	new[81]	coref	11-29[100_81]
9-23	1504-1510	immune	abstract[81]	new[81]	_	_
9-24	1511-1517	system	abstract[81]	new[81]	_	_
9-25	1518-1520	as	_	_	_	_
9-26	1521-1526	usual	substance[82]	new[82]	ana	10-5[0_82]
9-27	1527-1536	synthetic	substance[82]	new[82]	_	_
9-28	1537-1549	formulations	substance[82]	new[82]	_	_
9-29	1550-1552	do	_	_	_	_
9-30	1553-1554	.	_	_	_	_

#Text=In addition , given their phospholipid bilayer , EVs can directly fuse with the targeted plasma membrane , thus allowing a more efficient internalization of the encapsulated drug .
10-1	1555-1557	In	_	_	_	_
10-2	1558-1566	addition	_	_	_	_
10-3	1567-1568	,	_	_	_	_
10-4	1569-1574	given	_	_	_	_
10-5	1575-1580	their	substance|substance[85]	giv|new[85]	ana	11-1
10-6	1581-1593	phospholipid	abstract|substance[85]	new|new[85]	_	_
10-7	1594-1601	bilayer	substance[85]	new[85]	_	_
10-8	1602-1603	,	_	_	_	_
10-9	1604-1607	EVs	abstract	giv	coref	18-17
10-10	1608-1611	can	_	_	_	_
10-11	1612-1620	directly	_	_	_	_
10-12	1621-1625	fuse	_	_	_	_
10-13	1626-1630	with	_	_	_	_
10-14	1631-1634	the	object[88]	giv[88]	coref	15-7[0_88]
10-15	1635-1643	targeted	object[88]	giv[88]	_	_
10-16	1644-1650	plasma	substance|object[88]	new|giv[88]	_	_
10-17	1651-1659	membrane	object[88]	giv[88]	_	_
10-18	1660-1661	,	_	_	_	_
10-19	1662-1666	thus	_	_	_	_
10-20	1667-1675	allowing	_	_	_	_
10-21	1676-1677	a	abstract[89]	new[89]	_	_
10-22	1678-1682	more	abstract[89]	new[89]	_	_
10-23	1683-1692	efficient	abstract[89]	new[89]	_	_
10-24	1693-1708	internalization	abstract[89]	new[89]	_	_
10-25	1709-1711	of	abstract[89]	new[89]	_	_
10-26	1712-1715	the	abstract[89]|substance[90]	new[89]|giv[90]	coref	16-7[0_90]
10-27	1716-1728	encapsulated	abstract[89]|substance[90]	new[89]|giv[90]	_	_
10-28	1729-1733	drug	abstract[89]|substance[90]	new[89]|giv[90]	_	_
10-29	1734-1735	.	_	_	_	_

#Text=Their hydrophilic shell , together with the presence of anti-phagocytosis surface markers ( i.e. , CD47 ) , enables them to evade phagocytosis by monocytes and macrophages of the reticulo-endothelial system , hence weakening their clearance .
11-1	1736-1741	Their	substance|object[92]	giv|new[92]	ana	11-20
11-2	1742-1753	hydrophilic	object[92]	new[92]	_	_
11-3	1754-1759	shell	object[92]	new[92]	_	_
11-4	1760-1761	,	object[92]	new[92]	_	_
11-5	1762-1770	together	object[92]|abstract[93]	new[92]|new[93]	_	_
11-6	1771-1775	with	object[92]|abstract[93]	new[92]|new[93]	_	_
11-7	1776-1779	the	object[92]|abstract[93]	new[92]|new[93]	_	_
11-8	1780-1788	presence	object[92]|abstract[93]	new[92]|new[93]	_	_
11-9	1789-1791	of	object[92]|abstract[93]	new[92]|new[93]	_	_
11-10	1792-1809	anti-phagocytosis	object[92]|abstract[93]|abstract[95]	new[92]|new[93]|new[95]	ana	12-7[0_95]
11-11	1810-1817	surface	object[92]|abstract[93]|place|abstract[95]	new[92]|new[93]|new|new[95]	_	_
11-12	1818-1825	markers	object[92]|abstract[93]|abstract[95]	new[92]|new[93]|new[95]	_	_
11-13	1826-1827	(	_	_	_	_
11-14	1828-1832	i.e.	_	_	_	_
11-15	1833-1834	,	_	_	_	_
11-16	1835-1839	CD47	_	_	_	_
11-17	1840-1841	)	_	_	_	_
11-18	1842-1843	,	_	_	_	_
11-19	1844-1851	enables	_	_	_	_
11-20	1852-1856	them	substance	giv	ana	11-35
11-21	1857-1859	to	_	_	_	_
11-22	1860-1865	evade	_	_	_	_
11-23	1866-1878	phagocytosis	abstract	new	_	_
11-24	1879-1881	by	_	_	_	_
11-25	1882-1891	monocytes	animal	new	_	_
11-26	1892-1895	and	_	_	_	_
11-27	1896-1907	macrophages	animal[99]	new[99]	_	_
11-28	1908-1910	of	animal[99]	new[99]	_	_
11-29	1911-1914	the	animal[99]|abstract[100]	new[99]|giv[100]	_	_
11-30	1915-1935	reticulo-endothelial	animal[99]|abstract[100]	new[99]|giv[100]	_	_
11-31	1936-1942	system	animal[99]|abstract[100]	new[99]|giv[100]	_	_
11-32	1943-1944	,	_	_	_	_
11-33	1945-1950	hence	_	_	_	_
11-34	1951-1960	weakening	_	_	_	_
11-35	1961-1966	their	substance|abstract[102]	giv|new[102]	coref	17-17[143_0]
11-36	1967-1976	clearance	abstract[102]	new[102]	_	_
11-37	1977-1978	.	_	_	_	_

#Text=Moreover , the limited size allows them to efficiently extravasate through the inter-endothelial junctions and fenestrations of both existing and neo-synthesized vessels .
12-1	1979-1987	Moreover	_	_	_	_
12-2	1988-1989	,	_	_	_	_
12-3	1990-1993	the	abstract[103]	new[103]	_	_
12-4	1994-2001	limited	abstract[103]	new[103]	_	_
12-5	2002-2006	size	abstract[103]	new[103]	_	_
12-6	2007-2013	allows	_	_	_	_
12-7	2014-2018	them	abstract	giv	_	_
12-8	2019-2021	to	_	_	_	_
12-9	2022-2033	efficiently	_	_	_	_
12-10	2034-2045	extravasate	_	_	_	_
12-11	2046-2053	through	_	_	_	_
12-12	2054-2057	the	place[105]	new[105]	_	_
12-13	2058-2075	inter-endothelial	place[105]	new[105]	_	_
12-14	2076-2085	junctions	place[105]	new[105]	_	_
12-15	2086-2089	and	_	_	_	_
12-16	2090-2103	fenestrations	abstract[106]	new[106]	_	_
12-17	2104-2106	of	abstract[106]	new[106]	_	_
12-18	2107-2111	both	abstract[106]|object[107]	new[106]|giv[107]	_	_
12-19	2112-2120	existing	abstract[106]|object[107]	new[106]|giv[107]	_	_
12-20	2121-2124	and	abstract[106]|object[107]	new[106]|giv[107]	_	_
12-21	2125-2140	neo-synthesized	abstract[106]|object[107]	new[106]|giv[107]	_	_
12-22	2141-2148	vessels	abstract[106]|object[107]	new[106]|giv[107]	_	_
12-23	2149-2150	.	_	_	_	_

#Text=Thanks to these peculiar characteristics , they can spread and accumulate in the parenchyma of solid tumors .
13-1	2151-2157	Thanks	_	_	_	_
13-2	2158-2160	to	_	_	_	_
13-3	2161-2166	these	abstract[108]	new[108]	ana	13-7[0_108]
13-4	2167-2175	peculiar	abstract[108]	new[108]	_	_
13-5	2176-2191	characteristics	abstract[108]	new[108]	_	_
13-6	2192-2193	,	_	_	_	_
13-7	2194-2198	they	abstract	giv	_	_
13-8	2199-2202	can	_	_	_	_
13-9	2203-2209	spread	_	_	_	_
13-10	2210-2213	and	_	_	_	_
13-11	2214-2224	accumulate	_	_	_	_
13-12	2225-2227	in	_	_	_	_
13-13	2228-2231	the	time[110]	new[110]	_	_
13-14	2232-2242	parenchyma	time[110]	new[110]	_	_
13-15	2243-2245	of	time[110]	new[110]	_	_
13-16	2246-2251	solid	time[110]|object[111]	new[110]|new[111]	_	_
13-17	2252-2258	tumors	time[110]|object[111]	new[110]|new[111]	_	_
13-18	2259-2260	.	_	_	_	_

#Text=EV
14-1	2261-2263	EV	abstract	new	coref	20-14

#Text=biological properties derive from their sophisticated membrane structure , characterized by the presence of several proteins for active targeting , adhesion , cell fusion , and intracellular release of their content ; this functional complexity is not easily reproduced by de novo synthesized nanoparticles .
15-1	2264-2274	biological	substance[113]	new[113]	ana	15-5[0_113]
15-2	2275-2285	properties	substance[113]	new[113]	_	_
15-3	2286-2292	derive	_	_	_	_
15-4	2293-2297	from	_	_	_	_
15-5	2298-2303	their	substance|abstract[116]	giv|new[116]	ana	15-30
15-6	2304-2317	sophisticated	abstract[116]	new[116]	_	_
15-7	2318-2326	membrane	object|abstract[116]	giv|new[116]	_	_
15-8	2327-2336	structure	abstract[116]	new[116]	_	_
15-9	2337-2338	,	abstract[116]	new[116]	_	_
15-10	2339-2352	characterized	abstract[116]	new[116]	_	_
15-11	2353-2355	by	abstract[116]	new[116]	_	_
15-12	2356-2359	the	abstract[116]|abstract[117]	new[116]|new[117]	_	_
15-13	2360-2368	presence	abstract[116]|abstract[117]	new[116]|new[117]	_	_
15-14	2369-2371	of	abstract[116]|abstract[117]	new[116]|new[117]	_	_
15-15	2372-2379	several	abstract[116]|abstract[117]|substance[118]	new[116]|new[117]|giv[118]	_	_
15-16	2380-2388	proteins	abstract[116]|abstract[117]|substance[118]	new[116]|new[117]|giv[118]	_	_
15-17	2389-2392	for	abstract[116]|abstract[117]|substance[118]	new[116]|new[117]|giv[118]	_	_
15-18	2393-2399	active	abstract[116]|abstract[117]|substance[118]|event[119]	new[116]|new[117]|giv[118]|new[119]	coref	17-8[0_119]
15-19	2400-2409	targeting	abstract[116]|abstract[117]|substance[118]|event[119]	new[116]|new[117]|giv[118]|new[119]	_	_
15-20	2410-2411	,	abstract[116]|abstract[117]|substance[118]	new[116]|new[117]|giv[118]	_	_
15-21	2412-2420	adhesion	abstract[116]|abstract[117]|substance[118]|abstract	new[116]|new[117]|giv[118]|new	_	_
15-22	2421-2422	,	abstract[116]|abstract[117]|substance[118]	new[116]|new[117]|giv[118]	_	_
15-23	2423-2427	cell	abstract[116]|abstract[117]|substance[118]|place|event[122]	new[116]|new[117]|giv[118]|giv|new[122]	_	_
15-24	2428-2434	fusion	abstract[116]|abstract[117]|substance[118]|event[122]	new[116]|new[117]|giv[118]|new[122]	_	_
15-25	2435-2436	,	abstract[116]|abstract[117]|substance[118]	new[116]|new[117]|giv[118]	_	_
15-26	2437-2440	and	abstract[116]|abstract[117]|substance[118]	new[116]|new[117]|giv[118]	_	_
15-27	2441-2454	intracellular	abstract[116]|abstract[117]|substance[118]|event[123]	new[116]|new[117]|giv[118]|new[123]	_	_
15-28	2455-2462	release	abstract[116]|abstract[117]|substance[118]|event[123]	new[116]|new[117]|giv[118]|new[123]	_	_
15-29	2463-2465	of	abstract[116]|abstract[117]|substance[118]|event[123]	new[116]|new[117]|giv[118]|new[123]	_	_
15-30	2466-2471	their	abstract[116]|abstract[117]|substance[118]|event[123]|substance|abstract[125]	new[116]|new[117]|giv[118]|new[123]|giv|new[125]	_	_
15-31	2472-2479	content	abstract[116]|abstract[117]|substance[118]|event[123]|abstract[125]	new[116]|new[117]|giv[118]|new[123]|new[125]	_	_
15-32	2480-2481	;	_	_	_	_
15-33	2482-2486	this	abstract[126]	new[126]	_	_
15-34	2487-2497	functional	abstract[126]	new[126]	_	_
15-35	2498-2508	complexity	abstract[126]	new[126]	_	_
15-36	2509-2511	is	_	_	_	_
15-37	2512-2515	not	_	_	_	_
15-38	2516-2522	easily	_	_	_	_
15-39	2523-2533	reproduced	_	_	_	_
15-40	2534-2536	by	_	_	_	_
15-41	2537-2539	de	_	_	_	_
15-42	2540-2544	novo	_	_	_	_
15-43	2545-2556	synthesized	object[127]	giv[127]	_	_
15-44	2557-2570	nanoparticles	object[127]	giv[127]	_	_
15-45	2571-2572	.	_	_	_	_

#Text=Among the several types of nano-based drug delivery systems , liposomes are probably the most used , due to their non-toxicity and capacity to accommodate high amounts of compounds .
16-1	2573-2578	Among	_	_	_	_
16-2	2579-2582	the	place[128]	new[128]	_	_
16-3	2583-2590	several	place[128]	new[128]	_	_
16-4	2591-2596	types	place[128]	new[128]	_	_
16-5	2597-2599	of	place[128]	new[128]	_	_
16-6	2600-2610	nano-based	place[128]|abstract[131]	new[128]|giv[131]	_	_
16-7	2611-2615	drug	place[128]|substance|abstract[131]	new[128]|giv|giv[131]	coref	18-21
16-8	2616-2624	delivery	place[128]|abstract|abstract[131]	new[128]|giv|giv[131]	coref	18-21[152_0]
16-9	2625-2632	systems	place[128]|abstract[131]	new[128]|giv[131]	_	_
16-10	2633-2634	,	_	_	_	_
16-11	2635-2644	liposomes	substance	giv	ana	16-20
16-12	2645-2648	are	_	_	_	_
16-13	2649-2657	probably	_	_	_	_
16-14	2658-2661	the	_	_	_	_
16-15	2662-2666	most	_	_	_	_
16-16	2667-2671	used	_	_	_	_
16-17	2672-2673	,	_	_	_	_
16-18	2674-2677	due	_	_	_	_
16-19	2678-2680	to	_	_	_	_
16-20	2681-2686	their	substance|abstract[134]	giv|new[134]	_	_
16-21	2687-2699	non-toxicity	abstract[134]	new[134]	_	_
16-22	2700-2703	and	_	_	_	_
16-23	2704-2712	capacity	abstract[135]	new[135]	_	_
16-24	2713-2715	to	abstract[135]	new[135]	_	_
16-25	2716-2727	accommodate	abstract[135]	new[135]	_	_
16-26	2728-2732	high	abstract[135]|substance[136]	new[135]|new[136]	_	_
16-27	2733-2740	amounts	abstract[135]|substance[136]	new[135]|new[136]	_	_
16-28	2741-2743	of	abstract[135]|substance[136]	new[135]|new[136]	_	_
16-29	2744-2753	compounds	abstract[135]|substance[136]|substance	new[135]|new[136]|new	_	_
16-30	2754-2755	.	_	_	_	_

#Text=However , a still inadequate in vivo targeting efficiency together with a potential immunogenicity associated to liposomal formulations has limited their broad applicability in therapeutics .
17-1	2756-2763	However	_	_	_	_
17-2	2764-2765	,	_	_	_	_
17-3	2766-2767	a	abstract[140]	new[140]	_	_
17-4	2768-2773	still	abstract[140]	new[140]	_	_
17-5	2774-2784	inadequate	abstract[140]	new[140]	_	_
17-6	2785-2787	in	abstract[140]	new[140]	_	_
17-7	2788-2792	vivo	abstract|abstract[140]	new|new[140]	_	_
17-8	2793-2802	targeting	event|abstract[140]	giv|new[140]	_	_
17-9	2803-2813	efficiency	abstract[140]	new[140]	_	_
17-10	2814-2822	together	abstract[140]	new[140]	_	_
17-11	2823-2827	with	abstract[140]	new[140]	_	_
17-12	2828-2829	a	abstract[140]|abstract[141]	new[140]|new[141]	_	_
17-13	2830-2839	potential	abstract[140]|abstract[141]	new[140]|new[141]	_	_
17-14	2840-2854	immunogenicity	abstract[140]|abstract[141]	new[140]|new[141]	_	_
17-15	2855-2865	associated	abstract[140]|abstract[141]	new[140]|new[141]	_	_
17-16	2866-2868	to	abstract[140]|abstract[141]	new[140]|new[141]	_	_
17-17	2869-2878	liposomal	abstract[140]|abstract[141]|substance|substance[143]	new[140]|new[141]|new|giv[143]	ana	17-21[0_143]
17-18	2879-2891	formulations	abstract[140]|abstract[141]|substance[143]	new[140]|new[141]|giv[143]	_	_
17-19	2892-2895	has	_	_	_	_
17-20	2896-2903	limited	_	_	_	_
17-21	2904-2909	their	substance|abstract[145]	giv|new[145]	coref	20-14[167_0]
17-22	2910-2915	broad	abstract[145]	new[145]	_	_
17-23	2916-2929	applicability	abstract[145]	new[145]	_	_
17-24	2930-2932	in	_	_	_	_
17-25	2933-2945	therapeutics	abstract	new	_	_
17-26	2946-2947	.	_	_	_	_

#Text=Therefore , the greater specificity combined with the consequent limited induction of systemic side effects make EVs ideal vehicles for drug delivery .
18-1	2948-2957	Therefore	_	_	_	_
18-2	2958-2959	,	_	_	_	_
18-3	2960-2963	the	abstract[147]	new[147]	_	_
18-4	2964-2971	greater	abstract[147]	new[147]	_	_
18-5	2972-2983	specificity	abstract[147]	new[147]	_	_
18-6	2984-2992	combined	abstract[147]	new[147]	_	_
18-7	2993-2997	with	abstract[147]	new[147]	_	_
18-8	2998-3001	the	abstract[147]|event[148]	new[147]|new[148]	_	_
18-9	3002-3012	consequent	abstract[147]|event[148]	new[147]|new[148]	_	_
18-10	3013-3020	limited	abstract[147]|event[148]	new[147]|new[148]	_	_
18-11	3021-3030	induction	abstract[147]|event[148]	new[147]|new[148]	_	_
18-12	3031-3033	of	abstract[147]|event[148]	new[147]|new[148]	_	_
18-13	3034-3042	systemic	abstract[147]|event[148]|abstract[149]	new[147]|new[148]|new[149]	coref	21-29[182_149]
18-14	3043-3047	side	abstract[147]|event[148]|abstract[149]	new[147]|new[148]|new[149]	_	_
18-15	3048-3055	effects	abstract[147]|event[148]|abstract[149]	new[147]|new[148]|new[149]	_	_
18-16	3056-3060	make	_	_	_	_
18-17	3061-3064	EVs	abstract	giv	coref	19-18[159_0]
18-18	3065-3070	ideal	_	_	_	_
18-19	3071-3079	vehicles	_	_	_	_
18-20	3080-3083	for	_	_	_	_
18-21	3084-3088	drug	substance|abstract[152]	giv|giv[152]	ana|coref	19-7[0_152]|21-21
18-22	3089-3097	delivery	abstract[152]	giv[152]	_	_
18-23	3098-3099	.	_	_	_	_

#Text=Although this research field is in its infancy , in the last decade , the use of bio-engineered EVs for the delivery of cytotoxic molecules in preclinical models has produced encouraging results .
19-1	3100-3108	Although	_	_	_	_
19-2	3109-3113	this	abstract[154]	new[154]	coref	22-17[189_154]
19-3	3114-3122	research	abstract|abstract[154]	new|new[154]	coref	22-19
19-4	3123-3128	field	abstract[154]	new[154]	_	_
19-5	3129-3131	is	_	_	_	_
19-6	3132-3134	in	_	_	_	_
19-7	3135-3138	its	abstract|time[156]	giv|new[156]	coref	19-21[160_0]
19-8	3139-3146	infancy	time[156]	new[156]	_	_
19-9	3147-3148	,	_	_	_	_
19-10	3149-3151	in	_	_	_	_
19-11	3152-3155	the	time[157]	new[157]	_	_
19-12	3156-3160	last	time[157]	new[157]	_	_
19-13	3161-3167	decade	time[157]	new[157]	_	_
19-14	3168-3169	,	_	_	_	_
19-15	3170-3173	the	event[158]	new[158]	_	_
19-16	3174-3177	use	event[158]	new[158]	_	_
19-17	3178-3180	of	event[158]	new[158]	_	_
19-18	3181-3195	bio-engineered	event[158]|abstract[159]	new[158]|giv[159]	coref	23-19[0_159]
19-19	3196-3199	EVs	event[158]|abstract[159]	new[158]|giv[159]	_	_
19-20	3200-3203	for	event[158]	new[158]	_	_
19-21	3204-3207	the	event[158]|abstract[160]	new[158]|giv[160]	coref	23-21[196_160]
19-22	3208-3216	delivery	event[158]|abstract[160]	new[158]|giv[160]	_	_
19-23	3217-3219	of	event[158]|abstract[160]	new[158]|giv[160]	_	_
19-24	3220-3229	cytotoxic	event[158]|abstract[160]|substance[161]	new[158]|giv[160]|new[161]	coref	23-31[199_161]
19-25	3230-3239	molecules	event[158]|abstract[160]|substance[161]	new[158]|giv[160]|new[161]	_	_
19-26	3240-3242	in	event[158]|abstract[160]|substance[161]	new[158]|giv[160]|new[161]	_	_
19-27	3243-3254	preclinical	event[158]|abstract[160]|substance[161]|abstract[162]	new[158]|giv[160]|new[161]|new[162]	_	_
19-28	3255-3261	models	event[158]|abstract[160]|substance[161]|abstract[162]	new[158]|giv[160]|new[161]|new[162]	_	_
19-29	3262-3265	has	_	_	_	_
19-30	3266-3274	produced	_	_	_	_
19-31	3275-3286	encouraging	abstract[163]	new[163]	_	_
19-32	3287-3294	results	abstract[163]	new[163]	_	_
19-33	3295-3296	.	_	_	_	_

#Text=These experimental evidences , in addition to preliminary clinical data , indicate that EV formulations may not only enhance the safety and biodistribution of commonly used drugs , but also increase their efficacy .
20-1	3297-3302	These	abstract[164]	new[164]	_	_
20-2	3303-3315	experimental	abstract[164]	new[164]	_	_
20-3	3316-3325	evidences	abstract[164]	new[164]	_	_
20-4	3326-3327	,	_	_	_	_
20-5	3328-3330	in	_	_	_	_
20-6	3331-3339	addition	_	_	_	_
20-7	3340-3342	to	_	_	_	_
20-8	3343-3354	preliminary	abstract[165]	new[165]	_	_
20-9	3355-3363	clinical	abstract[165]	new[165]	_	_
20-10	3364-3368	data	abstract[165]	new[165]	_	_
20-11	3369-3370	,	_	_	_	_
20-12	3371-3379	indicate	_	_	_	_
20-13	3380-3384	that	_	_	_	_
20-14	3385-3387	EV	abstract|substance[167]	giv|giv[167]	_	_
20-15	3388-3400	formulations	substance[167]	giv[167]	_	_
20-16	3401-3404	may	_	_	_	_
20-17	3405-3408	not	_	_	_	_
20-18	3409-3413	only	_	_	_	_
20-19	3414-3421	enhance	_	_	_	_
20-20	3422-3425	the	abstract[168]	new[168]	_	_
20-21	3426-3432	safety	abstract[168]	new[168]	_	_
20-22	3433-3436	and	_	_	_	_
20-23	3437-3452	biodistribution	abstract[169]	new[169]	_	_
20-24	3453-3455	of	abstract[169]	new[169]	_	_
20-25	3456-3464	commonly	abstract[169]|substance[170]	new[169]|new[170]	ana	20-32[0_170]
20-26	3465-3469	used	abstract[169]|substance[170]	new[169]|new[170]	_	_
20-27	3470-3475	drugs	abstract[169]|substance[170]	new[169]|new[170]	_	_
20-28	3476-3477	,	_	_	_	_
20-29	3478-3481	but	_	_	_	_
20-30	3482-3486	also	_	_	_	_
20-31	3487-3495	increase	_	_	_	_
20-32	3496-3501	their	substance|abstract[172]	giv|new[172]	ana|coref	21-4[0_172]|21-12[177_0]
20-33	3502-3510	efficacy	abstract[172]	new[172]	_	_
20-34	3511-3512	.	_	_	_	_

#Text=For example , it has been demonstrated that the administration of EV-encapsulating chemotherapy drugs leads to a significant reduction of drug accumulation in off-target organs , thus preventing important side effects during standard clinical protocols .
21-1	3513-3516	For	_	_	_	_
21-2	3517-3524	example	_	_	_	_
21-3	3525-3526	,	_	_	_	_
21-4	3527-3529	it	abstract	giv	_	_
21-5	3530-3533	has	_	_	_	_
21-6	3534-3538	been	_	_	_	_
21-7	3539-3551	demonstrated	_	_	_	_
21-8	3552-3556	that	_	_	_	_
21-9	3557-3560	the	event[174]	new[174]	_	_
21-10	3561-3575	administration	event[174]	new[174]	_	_
21-11	3576-3578	of	event[174]	new[174]	_	_
21-12	3579-3595	EV-encapsulating	event[174]|abstract|substance[177]	new[174]|new|giv[177]	_	_
21-13	3596-3608	chemotherapy	event[174]|abstract|substance[177]	new[174]|new|giv[177]	_	_
21-14	3609-3614	drugs	event[174]|substance[177]	new[174]|giv[177]	_	_
21-15	3615-3620	leads	_	_	_	_
21-16	3621-3623	to	_	_	_	_
21-17	3624-3625	a	event[178]	new[178]	_	_
21-18	3626-3637	significant	event[178]	new[178]	_	_
21-19	3638-3647	reduction	event[178]	new[178]	_	_
21-20	3648-3650	of	event[178]	new[178]	_	_
21-21	3651-3655	drug	event[178]|substance|abstract[180]	new[178]|giv|new[180]	coref	23-21
21-22	3656-3668	accumulation	event[178]|abstract[180]	new[178]|new[180]	_	_
21-23	3669-3671	in	event[178]|abstract[180]	new[178]|new[180]	_	_
21-24	3672-3682	off-target	event[178]|abstract[180]|object[181]	new[178]|new[180]|giv[181]	_	_
21-25	3683-3689	organs	event[178]|abstract[180]|object[181]	new[178]|new[180]|giv[181]	_	_
21-26	3690-3691	,	_	_	_	_
21-27	3692-3696	thus	_	_	_	_
21-28	3697-3707	preventing	_	_	_	_
21-29	3708-3717	important	abstract[182]	giv[182]	_	_
21-30	3718-3722	side	abstract[182]	giv[182]	_	_
21-31	3723-3730	effects	abstract[182]	giv[182]	_	_
21-32	3731-3737	during	_	_	_	_
21-33	3738-3746	standard	abstract[183]	new[183]	_	_
21-34	3747-3755	clinical	abstract[183]	new[183]	_	_
21-35	3756-3765	protocols	abstract[183]	new[183]	_	_
21-36	3766-3767	.	_	_	_	_

#Text=An astonishing number of newly published papers perfectly depict the scientific community ’s authentic interest in this flourishing research field .
22-1	3768-3770	An	abstract[184]	new[184]	_	_
22-2	3771-3782	astonishing	abstract[184]	new[184]	_	_
22-3	3783-3789	number	abstract[184]	new[184]	_	_
22-4	3790-3792	of	abstract[184]	new[184]	_	_
22-5	3793-3798	newly	abstract[184]|object[185]	new[184]|new[185]	_	_
22-6	3799-3808	published	abstract[184]|object[185]	new[184]|new[185]	_	_
22-7	3809-3815	papers	abstract[184]|object[185]	new[184]|new[185]	_	_
22-8	3816-3825	perfectly	_	_	_	_
22-9	3826-3832	depict	_	_	_	_
22-10	3833-3836	the	abstract[187]	giv[187]	_	_
22-11	3837-3847	scientific	organization[186]|abstract[187]	giv[186]|giv[187]	_	_
22-12	3848-3857	community	organization[186]|abstract[187]	giv[186]|giv[187]	_	_
22-13	3858-3860	’s	organization[186]|abstract[187]	giv[186]|giv[187]	_	_
22-14	3861-3870	authentic	abstract[187]	giv[187]	_	_
22-15	3871-3879	interest	abstract[187]	giv[187]	_	_
22-16	3880-3882	in	abstract[187]	giv[187]	_	_
22-17	3883-3887	this	abstract[187]|abstract[189]	giv[187]|giv[189]	_	_
22-18	3888-3899	flourishing	abstract[187]|abstract[189]	giv[187]|giv[189]	_	_
22-19	3900-3908	research	abstract[187]|abstract|abstract[189]	giv[187]|giv|giv[189]	_	_
22-20	3909-3914	field	abstract[187]|abstract[189]	giv[187]|giv[189]	_	_
22-21	3915-3916	.	_	_	_	_

#Text=Nevertheless , the first aim of this review is to disclose an overview of the latest applications of EVs as drug delivery vehicles , focusing on the sources employed , the molecules selected , and the final intended targets .
23-1	3917-3929	Nevertheless	_	_	_	_
23-2	3930-3931	,	_	_	_	_
23-3	3932-3935	the	abstract[190]	new[190]	_	_
23-4	3936-3941	first	abstract[190]	new[190]	_	_
23-5	3942-3945	aim	abstract[190]	new[190]	_	_
23-6	3946-3948	of	abstract[190]	new[190]	_	_
23-7	3949-3953	this	abstract[190]|event[191]	new[190]|giv[191]	coref	24-6[201_191]
23-8	3954-3960	review	abstract[190]|event[191]	new[190]|giv[191]	_	_
23-9	3961-3963	is	_	_	_	_
23-10	3964-3966	to	_	_	_	_
23-11	3967-3975	disclose	_	_	_	_
23-12	3976-3978	an	abstract[192]	new[192]	_	_
23-13	3979-3987	overview	abstract[192]	new[192]	_	_
23-14	3988-3990	of	abstract[192]	new[192]	_	_
23-15	3991-3994	the	abstract[192]|abstract[193]	new[192]|new[193]	_	_
23-16	3995-4001	latest	abstract[192]|abstract[193]	new[192]|new[193]	_	_
23-17	4002-4014	applications	abstract[192]|abstract[193]	new[192]|new[193]	_	_
23-18	4015-4017	of	abstract[192]|abstract[193]	new[192]|new[193]	_	_
23-19	4018-4021	EVs	abstract[192]|abstract[193]|abstract	new[192]|new[193]|giv	coref	24-28
23-20	4022-4024	as	abstract[192]|abstract[193]	new[192]|new[193]	_	_
23-21	4025-4029	drug	abstract[192]|abstract[193]|substance|abstract[196]|object[197]	new[192]|new[193]|giv|giv[196]|giv[197]	_	_
23-22	4030-4038	delivery	abstract[192]|abstract[193]|abstract[196]|object[197]	new[192]|new[193]|giv[196]|giv[197]	_	_
23-23	4039-4047	vehicles	abstract[192]|abstract[193]|object[197]	new[192]|new[193]|giv[197]	_	_
23-24	4048-4049	,	_	_	_	_
23-25	4050-4058	focusing	_	_	_	_
23-26	4059-4061	on	_	_	_	_
23-27	4062-4065	the	abstract[198]	new[198]	_	_
23-28	4066-4073	sources	abstract[198]	new[198]	_	_
23-29	4074-4082	employed	abstract[198]	new[198]	_	_
23-30	4083-4084	,	_	_	_	_
23-31	4085-4088	the	substance[199]	giv[199]	_	_
23-32	4089-4098	molecules	substance[199]	giv[199]	_	_
23-33	4099-4107	selected	substance[199]	giv[199]	_	_
23-34	4108-4109	,	_	_	_	_
23-35	4110-4113	and	_	_	_	_
23-36	4114-4117	the	abstract[200]	new[200]	_	_
23-37	4118-4123	final	abstract[200]	new[200]	_	_
23-38	4124-4132	intended	abstract[200]	new[200]	_	_
23-39	4133-4140	targets	abstract[200]	new[200]	_	_
23-40	4141-4142	.	_	_	_	_

#Text=In the second part of the review , we will take a step back and bring attention to the basics of one of the main pitfalls concerning EVs : the urgent need for highly pure vesicle preparation .
24-1	4143-4145	In	_	_	_	_
24-2	4146-4149	the	_	_	_	_
24-3	4150-4156	second	_	_	_	_
24-4	4157-4161	part	_	_	_	_
24-5	4162-4164	of	_	_	_	_
24-6	4165-4168	the	event[201]	giv[201]	_	_
24-7	4169-4175	review	event[201]	giv[201]	_	_
24-8	4176-4177	,	_	_	_	_
24-9	4178-4180	we	person	giv	_	_
24-10	4181-4185	will	_	_	_	_
24-11	4186-4190	take	_	_	_	_
24-12	4191-4192	a	event[203]	new[203]	_	_
24-13	4193-4197	step	event[203]	new[203]	_	_
24-14	4198-4202	back	_	_	_	_
24-15	4203-4206	and	_	_	_	_
24-16	4207-4212	bring	_	_	_	_
24-17	4213-4222	attention	abstract	new	_	_
24-18	4223-4225	to	_	_	_	_
24-19	4226-4229	the	abstract[205]	new[205]	_	_
24-20	4230-4236	basics	abstract[205]	new[205]	_	_
24-21	4237-4239	of	abstract[205]	new[205]	_	_
24-22	4240-4243	one	abstract[205]|abstract[206]	new[205]|new[206]	appos	24-30[209_206]
24-23	4244-4246	of	abstract[205]|abstract[206]	new[205]|new[206]	_	_
24-24	4247-4250	the	abstract[205]|abstract[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
24-25	4251-4255	main	abstract[205]|abstract[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
24-26	4256-4264	pitfalls	abstract[205]|abstract[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
24-27	4265-4275	concerning	abstract[205]|abstract[206]|abstract[207]	new[205]|new[206]|new[207]	_	_
24-28	4276-4279	EVs	abstract[205]|abstract[206]|abstract[207]|abstract	new[205]|new[206]|new[207]|giv	_	_
24-29	4280-4281	:	_	_	_	_
24-30	4282-4285	the	abstract[209]	giv[209]	_	_
24-31	4286-4292	urgent	abstract[209]	giv[209]	_	_
24-32	4293-4297	need	abstract[209]	giv[209]	_	_
24-33	4298-4301	for	abstract[209]	giv[209]	_	_
24-34	4302-4308	highly	abstract[209]|abstract[211]	giv[209]|new[211]	_	_
24-35	4309-4313	pure	abstract[209]|abstract[211]	giv[209]|new[211]	_	_
24-36	4314-4321	vesicle	abstract[209]|object|abstract[211]	giv[209]|new|new[211]	_	_
24-37	4322-4333	preparation	abstract[209]|abstract[211]	giv[209]|new[211]	_	_
24-38	4334-4335	.	_	_	_	_
